455 related articles for article (PubMed ID: 28822792)
1. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
[TBL] [Abstract][Full Text] [Related]
2. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
[TBL] [Abstract][Full Text] [Related]
3. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
4. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
5. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
[TBL] [Abstract][Full Text] [Related]
6. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
7. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():158-161. PubMed ID: 28600150
[TBL] [Abstract][Full Text] [Related]
9. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
[TBL] [Abstract][Full Text] [Related]
10. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
Ravazzolo R; Cappato S; Bocciardi R
Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
[TBL] [Abstract][Full Text] [Related]
11. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
14. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.
Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K
Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433
[TBL] [Abstract][Full Text] [Related]
15. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
17. Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [
Botman E; Raijmakers PGHM; Yaqub M; Teunissen B; Netelenbos C; Lubbers W; Schwarte LA; Micha D; Bravenboer N; Schoenmaker T; de Vries TJ; Pals G; Smit JM; Koolwijk P; Trotter DG; Lammertsma AA; Eekhoff EMW
Bone; 2019 Jul; 124():1-6. PubMed ID: 30858149
[TBL] [Abstract][Full Text] [Related]
18. Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():115-119. PubMed ID: 28822791
[TBL] [Abstract][Full Text] [Related]
19. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease.
Akyuz G; Gencer-Atalay K; Ata P
Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
